CN Patent

CN102171214B — 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂

Assigned to Medivation Technologies LLC · Expires 2015-06-24 · 11y expired

What this patent protects

本发明公开了具有式(I)和式(II)所示结构的化合物，其中取代基Y、Z、A、B、R 1 、R 2 、R 3 、R 4 和R 5 如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了含有至少一种本文所述化合物的药物组合物以及本文所述化合物或药物组合物在治疗通过抑制PARP活性而改善的疾病、紊乱和病症中的用途。

USPTO Abstract

本发明公开了具有式(I)和式(II)所示结构的化合物，其中取代基Y、Z、A、B、R 1 、R 2 、R 3 、R 4 和R 5 如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了含有至少一种本文所述化合物的药物组合物以及本文所述化合物或药物组合物在治疗通过抑制PARP活性而改善的疾病、紊乱和病症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN102171214B
Jurisdiction
CN
Classification
—
Expires
2015-06-24
Drug substance claim
No
Drug product claim
No
Assignee
Medivation Technologies LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.